News Release
More-
April 1, 2025
The Opening of a new Office for Open Innovation in the Boston Area -
March 31, 2025
Kissei Initiates Phase III Clinical Trial for GnRH Antagonist "Linzagolix" Indicated for Endometriosis -
March 14, 2025
Kissei Initiates Additional Phase III Clinical Trial for Rovatirelin (KPS-0373) for the Treatment of Spinocerebellar Degeneration -
February 26, 2025
Submission of New Drug Application for GnRH Antagonist "Linzagolix" Indicated for Uterine Fibroids, in Japan -
January 21, 2025
Marketing Authorization for the Oral Spleen Tyrosine Kinase Inhibitor TAVALISSE® in South Korea
Topics
More-
February 3, 2025
The Third Quarter of FY2024 (February 3, 2025) -
February 3, 2025
R&D Pipeline as of February 2025 -
November 5, 2024
The Second Quarter of FY2024 (November 5, 2024) -
October 28, 2024
Annual Report 2024 -
October 28, 2024
Financial Data Book 2024
